E
Elias Anaissie
Researcher at University of Cincinnati
Publications - 373
Citations - 45035
Elias Anaissie is an academic researcher from University of Cincinnati. The author has contributed to research in topics: Transplantation & Multiple myeloma. The author has an hindex of 107, co-authored 372 publications receiving 42808 citations. Previous affiliations of Elias Anaissie include Pennsylvania State University & Celgene.
Papers
More filters
Journal ArticleDOI
Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative study.
Elias Anaissie,Victor L. Paetznick,Lisa G. Ensign,Ana Espinel-Ingroff,John N. Galgiani,Christopher A. Hitchcock,Mark LaRocco,Thomas F. Patterson,Michael A. Pfaller,John H. Rex,Michael G. Rinaldi +10 more
TL;DR: In this article, the authors conducted a multicenter study to evaluate the intralaboratory and inter-laboratory reproducibilities of a method that uses agitation to disperse these types of growth.
Journal ArticleDOI
Eight‐year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1
Maurizio Zangari,Frits van Rhee,Elias Anaissie,Mauricio Pineda-Roman,Jeffrey Haessler,John Crowley,Bart Barlogie +6 more
TL;DR: Adjusting for prognostic variables in multivariate and pair‐mate analyses, TT2 was superior to TT1 in terms of CR duration, event‐free and overall survival, and these results provide a basis for the prospective evaluation of the consolidation strategy in a randomized clinical trial design.
Journal ArticleDOI
Is it time to redefine the management of febrile neutropenia in cancer patients
Elias Anaissie,Saroj Vadhan-Raj +1 more
Journal ArticleDOI
International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.
Sarah Waheed,John D. Shaughnessy,Frits van Rhee,Yazan Alsayed,Bijay Nair,Elias Anaissie,Jackie Szymonifka,Antje Hoering,John Crowley,Bart Barlogie +9 more
TL;DR: Myeloma survival varies markedly with International Staging System classification, presence of cytogenetic abnormalities, and, especially, gene expression profiling‐based risk and delTP53 status, whose collective impact has not been examined in the context of specific therapies.
Journal ArticleDOI
Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem cell transplant patients.
TL;DR: In this paper, the authors evaluated the pharmacokinetics and safety of extended-interval dosing of prophylactic liposomal amphotericin B (L-AMB) in peripheral stem cell transplant recipients.